slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,101-65,130
Pages 2,605
Rows per page 30
Component
65,101-65,130 of 78,138
06
The slide highlights the competitive advantage of scale and recontactability, supported by a callout on consent rates and a metric on drug success probability.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Logic Chain1 hit
09
Includes a Manhattan plot visualization and a zoomed-in regional association plot.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
10
The chart is a dot plot showing odds ratios for various phenotypes related to TSLP.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
15
FxG likely stands for Functional Genomics. The slide uses a process flow diagram to illustrate the R&D pipeline.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The slide uses a timeline-based pipeline visualization common in biotech investor decks.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
The chart uses a swimmer plot format to visualize patient-level treatment duration, dose escalation, and response status.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
27
The slide uses a Gantt-style visualization to map clinical trial milestones (First Efficacy Assessment, 6-mo PFS/OS, 12-mo PFS/OS) against calendar quarters from 2023 to 2026.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The chart demonstrates superior efficacy of 23ME-00610 over anti-PD1 in stimulating IFNy across multiple cancer types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
29
The chart shows statistical significance (p<0.01 and p<0.0001) for the combination therapy.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses a combination of a biological process diagram and a line chart showing tumor cell reduction over time.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
Uses a bell curve distribution to illustrate the selection strategy for cases and controls.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide uses a comparative experimental design to show that AbCellera molecules (red) perform similarly or better than a reference molecule (black) in killing MAGE-A4+ cells while maintaining specificity (no activity in knockout cells).AbCellera | Investor Conference Presentation Deck | 14 slides · AbCellera
Conference presentation Investor relations 1 hit
10
The right side uses a dot-plot style visualization to represent the economic structure of a partnership, moving from R&D funding to commercial royalties.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a Gantt-style chart to show the progress of three assets (ABS-101, ABS-201, ABS-301) across development stages.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
13
The slide uses a split-screen approach: biological mechanism on the left, market sizing on the right.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The chart highlights a positive trend in US comps, reaching 2% in Q3 2023.a.k.a. Brands | Investor Presentation Deck | 14 slides · a.k.a. Brands
Pitch deck Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
07
The chart uses a stacked bar format to show both total revenue growth and the changing composition of product contributions over time.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Evidence1 hit
11
Includes product branding and dosing regimen details.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
12
The chart shows a steady increase in annual net sales for VIVITROL.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
13
Includes disclaimer regarding patent litigation and definition of R12M.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
17
The chart is currently empty, serving as a framework template for future data plotting.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
18
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
The radar chart represents a multi-dimensional optimization framework for drug development.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style visualization to represent drug development stages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to treated patients.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide highlights the mechanism of action and key benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
107
The slide highlights the transition to a direct-to-consumer model, aiming for 90% in the medium term.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
117
Includes a Business of Fashion (BoF) article snippet as external validation.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit